Improving the limit of detection for Sanger sequencing: A comparison of methodologies for KRAS variant detection

BioTechniques

Volumn 53, Issue 3, 2012, Pages 182-188

  Davidson, Colin J ^a   Zeringer, Emily ^d   Champion, Kristen J ^b   Gauthier, Marie Pierre ^a   Wang, Fawn ^a   Boonyaratanakornkit, Jerry ^c   Jones, Julie R ^b   Schreiber, Edgar ^a  

^a Life Technologies Corporation   (United States)

^b GREENWOOD GENETIC CENTER   (United States)

^c Life Technologies   (United States)

^d Life Technologies   (United States)

Author keywords

Capillary electrophoresis; Fragment analysis; Genotyping; KRAS; Mutation detection; Sanger sequencing; Variant detection

Indexed keywords

K RAS PROTEIN;

ARTICLE; CODON; FLUORESCENT DYE TERMINATOR SANGER SEQUENCING; GENETIC PROCEDURES; GENETIC VARIABILITY; HIGH RESOLUTION MELTING ANALYSIS; LIMIT OF DETECTION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SHIFTED TERMINATION ASSAY; SINGLE BASE EXTENSION;

CELL LINE; DNA; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, CAPILLARY; FLUORESCENT DYES; GENOME, HUMAN; GENOTYPING TECHNIQUES; HUMANS; LIMIT OF DETECTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84866424605     PISSN: 07366205     EISSN: 19409818     Source Type: Journal    
DOI: 10.2144/000113913     Document Type: Article

References (16)

1. Karnoub, A.E. and R.A. Weinberg. 2008. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9:517-531.
2. Minamoto, T., M. Mai, and Z. Ronai. 2000. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. Cancer Detect. Prev. 24:1-12.
3. Lièvre, A., J.B. Bachet, D. Le Corre, V. Boige, B. Landi, J.F. Emile, J.F. Côté, G. Tomasic, et al. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66:3992-3995.
4. Amado, R.G., M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D.J. Freeman, T. Juan, R. Sikorski, et al. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:1626-1634.
5. van Krieken, J.H., A. Jung, T. Kirchner, F. Carneiro, R. Seruca, F.T. Bosman, P. Quirke, J.F. Fléjou, et al. 2008. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453:417-431.
6. Pao, W., T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, et al. 2005. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e17.
7. Shackelford, W., S. Deng, K. Murayama, and J. Wang. 2004. A new technology for mutation detection. Ann. N. Y. Acad. Sci. 1022:257-262.
8. Di Fiore, F., F. Blanchard, F. Charbonnier, F. Le Pessot, A. Lamy, M.P. Galais, L. Bastit, A. Killian, et al. 2007. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 96:1166-1169.
9. Magnin, S., E. Viel, A. Baraquin, S. Valmary-Degano, B. Kantelip, J.L. Pretet, C. Mougin, M. Bigand, et al. 2011. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J. Mol. Diagn. 13:485-492.
10. Ogino, S., T. Kawasaki, M. Brahmandam, L. Yan, M. Cantor, C. Namgyal, M. Mino-Kenudson, G.Y. Lauwers, et al. 2005. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing J. Mol. Diagn. 7:413-421.
11. Simi, L., N. Pratesi, M. Vignoli, R. Sestini, F. Cianchi, R. Valanzano, S. Nobili, E. Mini, et al. 2008. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol. 130:247-253.
12. Franklin, W.A., J. Haney, M. Sugita, L. Bemis, A. Jimeno, and W.A. Messersmith. 2010. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J. Mol. Diagn. 12:43-50.
13. Tsiatis, A.C., A. Norris-Kirby, R.G. Roy, M.J. Hafez, C.D. Gocke, J.R. Eshleman, and K.M. Murphy. 2010. Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations. J. Mol. Diagn. 12:425-432.
14. Oliner, K., T. Juan, S. Suggs, M. Wolf, I. Sarosi, D.J. Freeman, T. Gyuris, W. Baron, et al. 2010. A comparability study of 5 commercial KRAS tests. Diagn. Pathol. 16:23.
15. Li, J., L. Wang, H. Mamon, M.H. Kulke, R. Berbeco, and G.M. Makrigiorgos. 2008. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat. Med. 14:579-584.
16. Milbury, C.A., J. Li, and G.M. Makrigiorgos. 2011. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res. 39:e2.